Article
Tropomyosin Receptor Kinase Inhibitors for the Treatment of TRK Fusion Cancer
23 Apr 2021
Abstract excerpt
Abstract Chromosomal rearrangements of NTRK1–3 resulting in gene fusions (NTRK gene fusions) have been clinically validated as oncogenic drivers in a wide range of human cancers. Typically, NTRK gene fusions involve both inter- and intrachromosomal fusions of the 5′ regions of a variety of genes with the 3′ regions of NTRK genes leading to TRK fusion proteins with constitutive, ligand-independent activation of...
Topics
Join the communities discussing this publication.